NYMOX PHARMACEUTICAL CORPORATION
NASDAQ : NYMX

NYMOX PHARMACEUTICAL CORPORATION

November 18, 2005 13:30 ET

Statins May Slow the Effects of Alzheimer's Disease According to New Study; Nymox (NASDAQ: NYMX) Has Global Patent Rights for Statin Drugs for the Treatment and Prevention of Alzheimer's Disease

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Nov 18, 2005) -

Cholesterol-lowering drugs like statins were found to slow the progression of Alzheimer's disease (AD) in a new three year study of 342 AD patients (J. Neurol. Neurosurg. Psychiatry December, 2005; 76:1624-1629). Researchers at the University of Lille and the University Hospital, Lille, France compared AD patients taking cholesterol-lowering medication including statins to AD patients with unmedicated high cholesterol levels and to AD patients with normal cholesterol. They found that the use of cholesterol-lowering medication significantly slowed the cognitive decline that is the hallmark of AD as compared to both the unmedicated high cholesterol group and the normal cholesterol group.

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) holds U.S. and global patent rights for the use of statin drugs for the prevention and treatment of AD.

Statins are a class of cholesterol-lowering drugs that are the biggest-selling prescription pills in pharmaceutical history with estimated 2004 global sales of up to $26 billion. Alzheimer's disease is the leading cause of dementia in the elderly, afflicting an estimated 4.5 million people in the U.S. alone.

The potential use of statins to treat Alzheimer's disease (AD) has been widely reported in the peer-reviewed medical literature, both in terms of clinical data, (such as The Lancet Neurology (Sept. 2005; 4:521-2), Arch Neurol. (July 2005; 62:1047-51 Neurology (May, 2005; 64:1531-8); Arch Neurol. (May 2005; 62:753-7); J Neurol Sci. (Mar, 2005; 229-230:147-50); Arch Gen Psychiatry (Feb. 2005; 62:217-24)) and possible mechanisms through which statins may prevent or slow the progression of Alzheimer's disease (such as J Neurosci Res (2005; 82:10-19), J Biol Chem (Aug 2005; M505268200), PLoS Med. (Jan. 2005; 2:e18); J Neurosci. (Jan. 2005; 25:299-307))

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX
    www.nymox.com